This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Efficacy of Artesunate + Amodiaquine Four Years After Its Introduction in Zanzibar

This study has suspended participant recruitment.
(Due to lack of malaria patients in Zanzibar the study has been suspended.)
Information provided by:
Karolinska University Hospital Identifier:
First received: April 23, 2007
Last updated: May 16, 2008
Last verified: May 2008
The purpose of this study is to assess the efficacy of artesuante + amodiaquine four years after its introduction as first line treatment for uncomplicated childhood malaria in Zanzibar. The hypothesis is that the treatment has a polymerase chain reaction (PCR)adjusted parasitological cure rate of at least 85% 42 days after treatment.

Condition Intervention Phase
Malaria Drug: artesunate + amodiaquine Phase 4

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Official Title: Efficacy of Artesunate + Amodiaquine Four Years After Its Introduction as New Treatment Policy for Uncomplicated Plasmodium Falciparum Malaria in Zanzibar

Resource links provided by NLM:

Further study details as provided by Karolinska University Hospital:

Primary Outcome Measures:
  • PCR adjusted parasitological cure rate by day 42.

Estimated Enrollment: 110
Study Start Date: May 2007

Ages Eligible for Study:   6 Months to 59 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age below 60 months
  • Weight ≥5kg
  • No general danger signs or severe malaria present (see &
  • History of fever within 24 hours OR axillary temperature ≥ 37.5Cº
  • No other cause of fever is detectable
  • No severe malnutrition
  • Presence of P. falciparum asexual parasite density between 2000- 200,000/ul
  • Guardian/Patient has understood the procedures of the study and is willing to participate
  • Patient able to come for stipulated follow up visits and has easy access to the Study Site

Exclusion Criteria:

  • Not able to drink or breastfeed
  • Persistent Vomiting
  • Recent history of convulsions
  • Lethargic or unconscious
  • Unable to sit or stand (as appropriate for age)
  • History of allergy to test drugs
  • History of intake of any drugs other than paracetamol and aspirin within 3 days
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00465257

Kivunge Cottage Hospital
Kivunge, North A District, Zanzibar, Tanzania
Sponsors and Collaborators
Karolinska University Hospital
Study Director: Anders Björkman, Professor Karolinska UH
Principal Investigator: Guida Rotlland, MD, MPH Karolinska UH
  More Information Identifier: NCT00465257     History of Changes
Other Study ID Numbers: ACOIII
Study First Received: April 23, 2007
Last Updated: May 16, 2008

Additional relevant MeSH terms:
Protozoan Infections
Parasitic Diseases
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Antimalarials processed this record on June 23, 2017